Loading company
Guardant Health, Inc.
GH · Nasdaq · Healthcare · Diagnostics and Research
Next earnings: November 4, 2026
$177.65+0.2%Sep 29 close
- 1M
- +10.0%
- 6M
- +106.1%
- 1Y
- +184.3%
- 5Y
- +41.3%
GH · Nasdaq · Healthcare · Diagnostics and Research
Next earnings: November 4, 2026
$177.65+0.2%Sep 29 close
Guardant Health, Inc. is scheduled to report next on November 4, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $335M | $232.1M | +44.33% |
| Profit | -$120.1M | -$99.9M | -20.26% |
| Profit per share | -$0.90 | -$0.80 | -12.50% |
| Free Cash Flow | -$69.5M | -$65.9M | -5.46% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Our second-quarter performance reflected broad-based momentum across the Guardant portfolio, with revenue increasing 44% year over year,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Guardant Health, Inc.’s Item 2.02 8-K filed July 30, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
A short summary of each call — what the quarter showed, what management expects and whether they delivered on what they said last time — with the full transcript underneath.
Source: Yahoo Finance, transcribed by Quartr. Speaker names and roles are as transcribed; analysts are sometimes unnamed.
Summaries of earlier calls are part of Pro.
Summaries of earlier calls are part of Pro.
Summaries of earlier calls are part of Pro.
Call summaries are part of Pro
A two-minute read of every Guardant Health, Inc. earnings call: the numbers that mattered, what management expects, whether they delivered on last quarter’s outlook, and what analysts asked that went unanswered.
See one first on , , or — open to everyone.
Summaries of earlier calls are part of Pro.
Summaries of earlier calls are part of Pro.